The role of epigenetics in the biology of multiple myeloma

K Dimopoulos; P Gimsing; K Grønbæk

doi:10.1038/bcj.2014.29

The role of epigenetics in the biology of multiple myeloma

K Dimopoulos, P Gimsing, K Grønbæk

Department of Clinical Medicine

75 Citations (Scopus)

Abstract

Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.

Original language	English
Article number	e207
Journal	Blood Cancer Journal
Volume	4
Issue number	5
Pages (from-to)	1-10
Number of pages	10
ISSN	2044-5385
DOIs	https://doi.org/10.1038/bcj.2014.29
Publication status	Published - May 2014

Keywords

Animals
DNA Methylation
Epigenesis, Genetic
Epigenomics
Humans
Multiple Myeloma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bcj.2014.29

Cite this

@article{df9e9013bf584028a85f9461ee380e5c,

title = "The role of epigenetics in the biology of multiple myeloma",

abstract = "Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.",

keywords = "Animals, DNA Methylation, Epigenesis, Genetic, Epigenomics, Humans, Multiple Myeloma",

author = "K Dimopoulos and P Gimsing and K Gr{\o}nb{\ae}k",

year = "2014",

month = may,

doi = "10.1038/bcj.2014.29",

language = "English",

volume = "4",

pages = "1--10",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "nature publishing group",

number = "5",

}

TY - JOUR

T1 - The role of epigenetics in the biology of multiple myeloma

AU - Dimopoulos, K

AU - Gimsing, P

AU - Grønbæk, K

PY - 2014/5

Y1 - 2014/5

N2 - Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.

AB - Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.

KW - Animals

KW - DNA Methylation

KW - Epigenesis, Genetic

KW - Epigenomics

KW - Humans

KW - Multiple Myeloma

U2 - 10.1038/bcj.2014.29

DO - 10.1038/bcj.2014.29

M3 - Review

C2 - 24786391

SN - 2044-5385

VL - 4

SP - 1

EP - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 5

M1 - e207

ER -

The role of epigenetics in the biology of multiple myeloma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this